2023
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Wang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.Peer-Reviewed Original ResearchConceptsSecond malignanciesAcute myeloid leukemiaOlder patientsMyelodysplastic syndromeMyeloproliferative neoplasmsHU usersHigh riskPolycythemia veraEssential thrombocythemiaRisk of SMAML/myelodysplastic syndromeClassical Philadelphia chromosome-negative myeloproliferative neoplasmsImpact of hydroxyureaRetrospective cohort studyUse of hydroxyureaPhiladelphia chromosome-negative myeloproliferative neoplasmsClassical myeloproliferative neoplasmsCumulative incidence probabilityCohort studyCytoreductive therapyPatient characteristicsMedian ageHU useMyeloid leukemiaSecondary myelofibrosis
2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States
Wang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 2021, 62: 2438-2447. PMID: 33899659, DOI: 10.1080/10428194.2021.1913142.Peer-Reviewed Original ResearchConceptsPopulation-based studyDNA methyltransferase inhibitorRARS patientsRefractory anemiaRing sideroblastsRed blood cell transfusion independenceEnd Results-Medicare databaseLower-risk myelodysplastic syndromesPopulation-based cohortMethyltransferase inhibitorRBC-TIMedian durationMedian survivalOlder patientsTransfusion independenceTreatment initiationMyelodysplastic syndromeClinical effectivenessBetter survivalLenalidomideTreatment groupsPatientsRS statusOlder adultsAnemia
2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†
Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2019, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemia, Refractory, with Excess of BlastsAzacitidineHumansMedicareMyelodysplastic SyndromesPropensity ScoreRetrospective StudiesUnited StatesConceptsHigh-risk myelodysplastic syndromeExcess blastsRefractory anemiaOverall survival benefitRetrospective cohort studyMedian OSOS benefitRAEB patientsCohort studySurvival benefitTherapy useMyelodysplastic syndromeClinical trialsLower riskMedicare dataPatientsPropensity scoreOlder adultsDiagnosisAnemiaQuartileUnited StatesAssociationEnd resultOSAssociation of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntimetabolites, AntineoplasticHumansMedicareMyelodysplastic SyndromesProportional Hazards ModelsUnited StatesConceptsMyelodysplastic syndromeOverall survivalHMA cyclesHMA therapyProvider experienceCox proportional hazards modelOlder MDS patientsMedian overall survivalPercent of patientsSEER-Medicare dataMultivariate logistic regressionProportional hazards modelHMA initiationClinical outcomesMDS patientsClinical trialsMedian numberHMA treatmentHazards modelPatientsSignificant associationLogistic regressionPopulation-level survivalSurvivalSyndromeRBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60: 3181-3187. PMID: 31170846, DOI: 10.1080/10428194.2019.1622700.Peer-Reviewed Original ResearchConceptsRBC transfusion independenceLR-MDS patientsTransfusion independenceHMA initiationRBC transfusionClinical effectivenessReal-life clinical effectivenessRed blood cell transfusionLower-risk myelodysplastic syndromesLow-risk MDS patientsRisk MDS patientsBlood cell transfusionRisk myelodysplastic syndromesHMA therapyLR-MDSCell transfusionMost patientsDisease courseMDS patientsMedicare databaseMyelodysplastic syndromePopulation-level estimatesLower oddsTransfusionPatients
2018
Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it
Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews 2018, 34: 1-15. PMID: 30314642, DOI: 10.1016/j.blre.2018.09.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCase ascertainmentAllogeneic hematopoietic stem cell transplantationAnnual age-adjusted incidenceHematopoietic stem cell transplantationOutcomes of patientsAge-adjusted incidenceStem cell transplantationAcute myeloid leukemiaTraditional morphologic assessmentClassification of MDSVariable cytopeniasCell transplantationMyelodysplastic syndromePrior receiptInefficient hematopoiesisEffective therapyMale genderRisk factorsMyeloid leukemiaEpidemiological trendsTreatment decisionsMyeloid neoplasmsEpidemiological assessmentDiagnostic criteriaTemporal improvementSelection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States
Ma X, Steensma DP, Scott BL, Kiselev P, Sugrue MM, Swern AS. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. BMJ Open 2018, 8: e019955. PMID: 30037860, PMCID: PMC6059277, DOI: 10.1136/bmjopen-2017-019955.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnemiaAzacitidineDatabases, FactualDecitabineElectronic Health RecordsEnzyme InhibitorsFemaleHematinicsHumansImmunologic FactorsIron Chelating AgentsLenalidomideMaleMiddle AgedMultivariate AnalysisMyelodysplastic SyndromesProportional Hazards ModelsRecurrenceRetrospective StudiesThalidomideTreatment OutcomeUnited StatesConceptsDisease-modifying therapiesErythropoiesis-stimulating agentsElectronic medical record databaseMyelodysplastic syndromeMedical record databasePatient characteristicsTreatment patternsGE Centricity Electronic Medical Records databaseRecord databaseLow baseline hemoglobin levelMultivariable Cox regression modelsLarge electronic medical record databaseBaseline hemoglobin levelAbsence of comorbiditiesFirst-line treatmentMajority of patientsSelection of patientsCox regression modelIron chelation therapyAgent azacitidineMore comorbiditiesHemoglobin levelsMale genderClinical trialsChelation therapyCounseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer Journal 2018, 8: 55. PMID: 29891916, PMCID: PMC5995881, DOI: 10.1038/s41408-018-0081-8.Peer-Reviewed Original Research
2017
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 2017, 131: 818-821. PMID: 29259002, PMCID: PMC6410557, DOI: 10.1182/blood-2017-10-811729.Peer-Reviewed Original Research
2016
Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study
Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study. The Prostate 2016, 77: 437-445. PMID: 27868212, PMCID: PMC5785924, DOI: 10.1002/pros.23281.Peer-Reviewed Original ResearchConceptsMDS/acute myeloid leukemiaAcute myeloid leukemiaProstate cancer patientsElderly prostate cancer patientsImpact of radiotherapyCancer patientsMyelodysplastic syndromeNational Cancer Institute's SurveillanceSubsequent myelodysplastic syndromeEnd Results-MedicareRetrospective cohort studyRole of radiotherapyInformed treatment decisionsUnderwent radiotherapyIMRT groupCohort studyPatient characteristicsMedian timeMyeloid leukemiaProstate cancerTreatment decisionsPatientsRadiotherapyMyeloid malignanciesSurgeryComparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal Of Haematology 2016, 175: 829-840. PMID: 27650975, DOI: 10.1111/bjh.14305.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeRAEB patientsMedian survivalClinical trialsMultivariate Cox proportional hazards modelCox proportional hazards modelKaplan-Meier methodPopulation-based survivalSignificant survival differenceComparative clinical effectivenessProportional hazards modelAgent azacitidineHMA initiationExcess blastsOlder patientsRandomized trialsHistological subtypesRefractory anemiaClinical effectivenessSurvival differencesSubset analysisSurvival advantageHazards modelPatientsDecitabineConnect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer 2016, 16: 652. PMID: 27538433, PMCID: PMC4991094, DOI: 10.1186/s12885-016-2710-6.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesProspective StudiesQuality of LifeRegistriesSample SizeUnited StatesConceptsAcute myeloid leukemiaObservational cohort studyDisease RegistryCohort studyClinical outcomesPatient-reported health-related qualityProspective observational cohort studyBaseline patient characteristicsHigh-risk MDSHealth-related qualityNon-interventional studyPatient-reported outcomesLower-risk MDSHealth economic outcomesMinimal diagnostic criteriaRoutine clinical settingNatural history studiesBackgroundMyelodysplastic syndromesPersistent cytopeniasOlder patientsPatient characteristicsTreatment patternsAlternate diagnosisCentral reviewMyelodysplastic syndromeDisease‐related costs of care and survival among Medicare‐enrolled patients with myelodysplastic syndromes
Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X. Disease‐related costs of care and survival among Medicare‐enrolled patients with myelodysplastic syndromes. Cancer 2016, 122: 1598-1607. PMID: 26970288, PMCID: PMC5509410, DOI: 10.1002/cncr.29945.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overFemaleHealth Care CostsHumansMaleMedicareMyelodysplastic SyndromesRegistriesSEER ProgramUnited StatesConceptsMyelodysplastic syndromeEligible patientsHazard ratioMedicare beneficiariesMultivariate Cox proportional hazards modelEnd Results-Medicare databasePropensity score-matched groupsCox proportional hazards modelOverall study populationSubgroup of patientsConfidence intervalsCost-saving interventionEnd of studyProportional hazards modelElderly patientsOverall survivalDisease characteristicsMDS cohortPatient outcomesStudy populationInternational ClassificationWarrants additional researchHazards modelPatientsSurvival rate
2012
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes
Wang R, Gross CP, Frick K, Xu X, Long J, Raza A, Galili N, Zikria J, Guan Y, Ma X. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leukemia Research 2012, 36: 1370-1375. PMID: 22917770, PMCID: PMC3458648, DOI: 10.1016/j.leukres.2012.07.020.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAzacitidineDecitabineDrug CostsEnzyme InhibitorsFemaleHumansMaleMyelodysplastic SyndromesSEER ProgramConceptsCost of careMyelodysplastic syndromeMDS patientsMedicare expendituresComparative cost-effectiveness studyCohort of patientsTwo-year survivalNon-cancer controlsCost-effectiveness studiesElderly patientsPrevalent cancerEconomic burdenPatientsMajor subtypesSurvivalCareSyndromeUnited StatesHMAsSurvival probabilityEarly periodCohortAgentsCancerSubtypesEpidemiology of Myelodysplastic Syndromes
Ma X. Epidemiology of Myelodysplastic Syndromes. The American Journal Of Medicine 2012, 125: s2-s5. PMID: 22735748, PMCID: PMC3394456, DOI: 10.1016/j.amjmed.2012.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolHumansIncidenceInfantInfant, NewbornMiddle AgedMyelodysplastic SyndromesPrevalencePrognosisConceptsMyelodysplastic syndromeIncidence of MDSBetter risk-stratify patientsClonal hematopoietic stem cell malignanciesHematopoietic stem cell malignanciesRisk-stratify patientsStem cell malignanciesMore effective treatmentsMDS prognosisDifferent comorbiditiesPrognostic factorsSignificant morbidityEtiologic factorsDisease burdenPoor survivalEffective treatmentCell malignanciesHigh mortalityNew casesHeterogeneous groupComorbiditiesSyndromeDiseaseRecent studiesPotential interactions
2011
Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes
Ma X, Wang R, Galili N, Mayne ST, Wang SA, Yu H, Raza A. Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. Cancer Causes & Control 2011, 22: 623-629. PMID: 21287258, PMCID: PMC3086405, DOI: 10.1007/s10552-011-9735-6.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedMyelodysplastic SyndromesPrognosisRisk FactorsSex CharacteristicsSmokingSurvival AnalysisTime FactorsConceptsLower-risk myelodysplastic syndromesSurvival of patientsRisk of deathMyelodysplastic syndromeMDS survivalLifestyle factorsMultivariate Cox proportional hazards modelHigh-risk myelodysplastic syndromeCox proportional hazards modelLow-risk patientsProportional hazards modelInitial clinical encounterClinical characteristicsHazard ratioIndependent predictorsPrognostic roleMDS patientsCigarette smokingPoor survivalHematological malignanciesElevated riskHazards modelPatientsSmokingClinical encounters
2010
Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes
Wang R, Gross CP, Maggiore RJ, Halene S, Soulos PR, Raza A, Galili N, Ma X. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Leukemia Research 2010, 35: 904-908. PMID: 21067809, PMCID: PMC3114277, DOI: 10.1016/j.leukres.2010.10.007.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromePatient characteristicsRefractory anemiaMultivariate logistic regression modelMultiple patient characteristicsPopulation-based studyUse of HMAsLogistic regression modelsElderly patientsExcess blastsMultilineage dysplasiaRefractory cytopeniaMDS patientsPatientsComorbiditiesAnemiaSyndromeHigher chanceRegression modelsHMAsAgentsIntroduction periodCytopeniasDysplasiaCancer
2009
Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States
Wang R, Gross CP, Halene S, Ma X. Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States. Cancer Causes & Control 2009, 20: 1369-1376. PMID: 19455395, PMCID: PMC2921772, DOI: 10.1007/s10552-009-9362-7.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overFemaleHumansMaleMyelodysplastic SyndromesResidence CharacteristicsSocial ClassSurvival AnalysisUnited StatesConceptsNeighborhood socioeconomic statusMyelodysplastic syndromeSocioeconomic statusElderly patientsHazard ratioMultivariate Cox proportional hazards modelCox proportional hazards modelSurvival of patientsPopulation-based studyRisk of deathRisk of mortalityProportional hazards modelImpact of SESLow socioeconomic statusCensus tractsPrognostic roleMDS patientsIndependent determinantsRefractory anemiaHistological subtypesHazards modelPatientsSES statusTractS scoresObesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort
Ma X, Lim U, Park Y, Mayne ST, Wang R, Hartge P, Hollenbeck AR, Schatzkin A. Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort. American Journal Of Epidemiology 2009, 169: 1492-1499. PMID: 19395696, PMCID: PMC2727203, DOI: 10.1093/aje/kwp074.Peer-Reviewed Original ResearchConceptsRisk of MDSMyelodysplastic syndromeLifestyle factorsPhysical activityUS prospective studiesHealth-AARP DietLarge US cohortModifiable risk factorsBody mass indexRelation of obesityCurrent smokersFormer smokersMass indexSignificant positive associationAlcohol intakeCigarette smokingProspective studyProspective InvestigationUS cohortVegetable intakeRisk factorsMeat intakeHealth StudyAlcohol consumptionSmokersComorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes
Wang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leukemia Research 2009, 33: 1594-1598. PMID: 19324411, PMCID: PMC2749891, DOI: 10.1016/j.leukres.2009.02.005.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCohort StudiesComorbidityFemaleHumansMaleMyelodysplastic SyndromesProportional Hazards ModelsConceptsMyelodysplastic syndromeHazard ratioComorbid conditionsMDS patientsCharlson indexMultivariate Cox proportional hazards modelPrognosis of MDSChronic obstructive pulmonary diseaseCox proportional hazards modelLarge population-based studyCongestive heart failureObstructive pulmonary diseaseRole of comorbiditiesMedian survival timePopulation-based studyProportional hazards modelMDS survivalHeart failurePulmonary diseaseIndependent determinantsShorter survivalLarge cohortSurvival timeHazards modelComorbidities